U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C13H16N2.H3O4P
Molecular Weight 298.2747
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of TETRAHYDROZOLINE PHOSPHATE

SMILES

OP(O)(O)=O.C1CN=C(N1)C2CCCC3=CC=CC=C23

InChI

InChIKey=HPGQQPUQEIRXHP-UHFFFAOYSA-N
InChI=1S/C13H16N2.H3O4P/c1-2-6-11-10(4-1)5-3-7-12(11)13-14-8-9-15-13;1-5(2,3)4/h1-2,4,6,12H,3,5,7-9H2,(H,14,15);(H3,1,2,3,4)

HIDE SMILES / InChI

Molecular Formula H3O4P
Molecular Weight 97.9952
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C13H16N2
Molecular Weight 200.2795
Charge 0
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

Tetrahydrozoline is an alpha adrenergic receptor agonist, which is used in form of nasal solution or spray (Tyzin) for decongestion of nasal and nasopharyngeal mucosa.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: CHEMBL2095203
Sources: www.ncbi.nlm.nih.gov/pubmed/18259967
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
TYZINE

Approved Use

Tyzine Nasal Solution is indicated for decongestion of nasal and nasopharyngeal mucosa.

Launch Date

1979
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
0.218 ng/mL
2 drop 4 times / day multiple, ocular
dose: 2 drop
route of administration: Ocular
experiment type: MULTIPLE
co-administered:
TETRAHYDROZOLINE serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
3.46 ng × h/mL
2 drop 4 times / day multiple, ocular
dose: 2 drop
route of administration: Ocular
experiment type: MULTIPLE
co-administered:
TETRAHYDROZOLINE serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
6 h
2 drop 4 times / day multiple, ocular
dose: 2 drop
route of administration: Ocular
experiment type: MULTIPLE
co-administered:
TETRAHYDROZOLINE serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
7500 ug single, oral
Overdose
Dose: 7500 ug
Route: oral
Route: single
Dose: 7500 ug
Sources:
healthy, 16 years
n = 1
Health Status: healthy
Age Group: 16 years
Sex: M
Population Size: 1
Sources:
Other AEs: Sinoatrial node dysfunction...
Other AEs:
Sinoatrial node dysfunction (1 patient)
Sources:
0.3 mg/kg single, oral
Overdose
Dose: 0.3 mg/kg
Route: oral
Route: single
Dose: 0.3 mg/kg
Sources:
healthy, 20 months-2 years
n = 2
Health Status: healthy
Age Group: 20 months-2 years
Sex: M+F
Population Size: 2
Sources:
Other AEs: Bradycardia, Hypertension...
Other AEs:
Bradycardia (2 patients)
Hypertension (1 patient)
Gasping (2 patients)
Sources:
250 ug 3 times / day multiple, oral
Overdose
Dose: 250 ug, 3 times / day
Route: oral
Route: multiple
Dose: 250 ug, 3 times / day
Sources:
unhealthy, 25 days
n = 1
Health Status: unhealthy
Age Group: 25 days
Sex: M
Population Size: 1
Sources:
Other AEs: Hypotonia...
Other AEs:
Hypotonia (1 patient)
Sources:
250 ug 3 times / day multiple, oral
Overdose
Dose: 250 ug, 3 times / day
Route: oral
Route: multiple
Dose: 250 ug, 3 times / day
Sources:
unhealthy, 25 days
n = 1
Health Status: unhealthy
Condition: mild fever
Age Group: 25 days
Sex: M
Population Size: 1
Sources:
Other AEs: Apnea...
Other AEs:
Apnea (1 patient)
Sources:
15000 ug single, oral
Overdose
Dose: 15000 ug
Route: oral
Route: single
Dose: 15000 ug
Sources:
healthy, 41 years
n = 1
Health Status: healthy
Age Group: 41 years
Sex: M
Population Size: 1
Sources:
Other AEs: Hypothermia, Bradycardia...
Other AEs:
Hypothermia (1 patient)
Bradycardia (1 patient)
Hypotension (1 patient)
Miosis (1 patient)
Lethargy (1 patient)
Mucous membrane disorder (NOS) (1 patient)
Bowel sounds decreased (1 patient)
Chest pain (1 patient)
Sources:
AEs

AEs

AESignificanceDosePopulation
Sinoatrial node dysfunction 1 patient
7500 ug single, oral
Overdose
Dose: 7500 ug
Route: oral
Route: single
Dose: 7500 ug
Sources:
healthy, 16 years
n = 1
Health Status: healthy
Age Group: 16 years
Sex: M
Population Size: 1
Sources:
Hypertension 1 patient
0.3 mg/kg single, oral
Overdose
Dose: 0.3 mg/kg
Route: oral
Route: single
Dose: 0.3 mg/kg
Sources:
healthy, 20 months-2 years
n = 2
Health Status: healthy
Age Group: 20 months-2 years
Sex: M+F
Population Size: 2
Sources:
Bradycardia 2 patients
0.3 mg/kg single, oral
Overdose
Dose: 0.3 mg/kg
Route: oral
Route: single
Dose: 0.3 mg/kg
Sources:
healthy, 20 months-2 years
n = 2
Health Status: healthy
Age Group: 20 months-2 years
Sex: M+F
Population Size: 2
Sources:
Gasping 2 patients
0.3 mg/kg single, oral
Overdose
Dose: 0.3 mg/kg
Route: oral
Route: single
Dose: 0.3 mg/kg
Sources:
healthy, 20 months-2 years
n = 2
Health Status: healthy
Age Group: 20 months-2 years
Sex: M+F
Population Size: 2
Sources:
Hypotonia 1 patient
250 ug 3 times / day multiple, oral
Overdose
Dose: 250 ug, 3 times / day
Route: oral
Route: multiple
Dose: 250 ug, 3 times / day
Sources:
unhealthy, 25 days
n = 1
Health Status: unhealthy
Age Group: 25 days
Sex: M
Population Size: 1
Sources:
Apnea 1 patient
250 ug 3 times / day multiple, oral
Overdose
Dose: 250 ug, 3 times / day
Route: oral
Route: multiple
Dose: 250 ug, 3 times / day
Sources:
unhealthy, 25 days
n = 1
Health Status: unhealthy
Condition: mild fever
Age Group: 25 days
Sex: M
Population Size: 1
Sources:
Bowel sounds decreased 1 patient
15000 ug single, oral
Overdose
Dose: 15000 ug
Route: oral
Route: single
Dose: 15000 ug
Sources:
healthy, 41 years
n = 1
Health Status: healthy
Age Group: 41 years
Sex: M
Population Size: 1
Sources:
Bradycardia 1 patient
15000 ug single, oral
Overdose
Dose: 15000 ug
Route: oral
Route: single
Dose: 15000 ug
Sources:
healthy, 41 years
n = 1
Health Status: healthy
Age Group: 41 years
Sex: M
Population Size: 1
Sources:
Chest pain 1 patient
15000 ug single, oral
Overdose
Dose: 15000 ug
Route: oral
Route: single
Dose: 15000 ug
Sources:
healthy, 41 years
n = 1
Health Status: healthy
Age Group: 41 years
Sex: M
Population Size: 1
Sources:
Hypotension 1 patient
15000 ug single, oral
Overdose
Dose: 15000 ug
Route: oral
Route: single
Dose: 15000 ug
Sources:
healthy, 41 years
n = 1
Health Status: healthy
Age Group: 41 years
Sex: M
Population Size: 1
Sources:
Hypothermia 1 patient
15000 ug single, oral
Overdose
Dose: 15000 ug
Route: oral
Route: single
Dose: 15000 ug
Sources:
healthy, 41 years
n = 1
Health Status: healthy
Age Group: 41 years
Sex: M
Population Size: 1
Sources:
Lethargy 1 patient
15000 ug single, oral
Overdose
Dose: 15000 ug
Route: oral
Route: single
Dose: 15000 ug
Sources:
healthy, 41 years
n = 1
Health Status: healthy
Age Group: 41 years
Sex: M
Population Size: 1
Sources:
Miosis 1 patient
15000 ug single, oral
Overdose
Dose: 15000 ug
Route: oral
Route: single
Dose: 15000 ug
Sources:
healthy, 41 years
n = 1
Health Status: healthy
Age Group: 41 years
Sex: M
Population Size: 1
Sources:
Mucous membrane disorder (NOS) 1 patient
15000 ug single, oral
Overdose
Dose: 15000 ug
Route: oral
Route: single
Dose: 15000 ug
Sources:
healthy, 41 years
n = 1
Health Status: healthy
Age Group: 41 years
Sex: M
Population Size: 1
Sources:
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Gingival tissue inflammatory response following treatment with chemical retraction agents in Beagle dogs.
2001
Electron microscopic analysis of the effects of chemical retraction agents on cultured rat keratinocytes.
2002 Jan
Simultaneous determination of ofloxacin, tetrahydrozoline hydrochloride, and prednisolone acetate by high-performance liquid chromatography.
2002 Sep
[The tolerability of nasal drugs with special regard to preservatives and physico-chemical parameters].
2003 Nov
[Acute exposure to imidazoline derivatives in children].
2003 Nov-Dec
Sinoatrial node arrest following tetrahydrozoline ingestion.
2004 Oct
Effects of two eye drop products on computer users with subjective ocular discomfort.
2005 Jan
[Systemic involvement in premature infants after intranasal administration of tetryzoline drops].
2005 Oct
Drug facilitated sexual assault using an over-the-counter ocular solution containing tetrahydrozoline (Visine).
2007 Jul
Development of a multicommutated flow system with chemiluminometric detection for quantification of gentamicin in pharmaceuticals.
2010
Determination of tetrahydrozoline in urine and blood using gas chromatography-mass spectrometry (GC-MS).
2010
2-(1,2,3,4-Tetra-hydro-1-naphth-yl)imidazolium chloride monohydrate.
2010 Aug 18
A comparative kinetic and mechanistic study between tetrahydrozoline and naphazoline toward photogenerated reactive oxygen species.
2010 Jan-Feb
Naloxone use in a newborn with apnea due to tetrahydrozoline intoxication.
2010 Jun
Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2.
2011 Jul 14
Tetrahydrozoline (Visine®) concentrations in serum and urine during therapeutic ocular dosing: a necessary first step in determining an overdose.
2011 Nov
Patents

Sample Use Guides

Adults and Children 6 Years and Over, Tyzine 0.1% Nasal Solution: It is recommended that 2 to 4 drops be instilled in each nostril as needed, never more often than every three hours. Adults and Children 6 Years and Over, Tyzine 0.1% Nasal Spray: It is recommended to squeeze quickly and firmly three or four times the spray in each nostril as needed, never more often than every three hours. Children 2 to 6 Years of Age, Tyzine 0.05 % Pediatric Nasal Drops: It is recommended that 2 to 3 drops be instilled in each nostril as needed, and never more often than every three hours.
Route of Administration: Nasal
In Vitro Use Guide
Rat and rabbit aortae were treated with tetrahydrozoline at concentrations from 10(-7) to 10(-5) M to determine the drug relative efficacy. Emax value was 0.51 for the rabbit aortae and 0 for the rat aortae.
Substance Class Chemical
Created
by admin
on Sat Dec 16 10:01:16 GMT 2023
Edited
by admin
on Sat Dec 16 10:01:16 GMT 2023
Record UNII
79V49ERS3O
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
TETRAHYDROZOLINE PHOSPHATE
Common Name English
Tetryzoline phosphate [WHO-DD]
Common Name English
TETRYZOLINE PHOSPHATE
WHO-DD  
Common Name English
1H-IMIDAZOLE, 4,5-DIHYDRO-2-(1,2,3,4-TETRAHYDRO-1-NAPHTHALENYL)-, PHOSPHATE (1:1)
Systematic Name English
Code System Code Type Description
CAS
94133-85-4
Created by admin on Sat Dec 16 10:01:16 GMT 2023 , Edited by admin on Sat Dec 16 10:01:16 GMT 2023
PRIMARY
FDA UNII
79V49ERS3O
Created by admin on Sat Dec 16 10:01:16 GMT 2023 , Edited by admin on Sat Dec 16 10:01:16 GMT 2023
PRIMARY
SMS_ID
100000165745
Created by admin on Sat Dec 16 10:01:16 GMT 2023 , Edited by admin on Sat Dec 16 10:01:16 GMT 2023
PRIMARY
EVMPD
SUB179595
Created by admin on Sat Dec 16 10:01:16 GMT 2023 , Edited by admin on Sat Dec 16 10:01:16 GMT 2023
PRIMARY
ECHA (EC/EINECS)
302-749-1
Created by admin on Sat Dec 16 10:01:16 GMT 2023 , Edited by admin on Sat Dec 16 10:01:16 GMT 2023
PRIMARY
EPA CompTox
DTXSID90916383
Created by admin on Sat Dec 16 10:01:16 GMT 2023 , Edited by admin on Sat Dec 16 10:01:16 GMT 2023
PRIMARY
PUBCHEM
44152200
Created by admin on Sat Dec 16 10:01:16 GMT 2023 , Edited by admin on Sat Dec 16 10:01:16 GMT 2023
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY